Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia
Journal of Medicinal Chemistry · 25.01.2024 · 67 (2) · 1513-1532
DOI: 10.1021/acs.jmedchem.3c02104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 04.01.2024. Verfasst von Wenhua Jiang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China. Hauptthemen laut MEDLINE: Transcription Factors, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Bromodomain-selective BET inhibition has emerged as a promising strategy to improve the safety profiles of pan-BET inhibitors. Herein, we report the discovery of potent phenoxyaryl pyridones as highly BD2-selective BET inhibitors. Compound 23 (IC50 = 2.9 nM) exhibited a comparable BRD4 BD2 inhibitory activity relative to 10 (IC50 = 1.0 nM) and remarkably improved selectivity over BRD4 BD1 (23: 2583-fold; 10: 344-fold). This lead compound significantly inhibited the proliferation of acute myeloid leukemia (AML) cell lines through induction of G0/G1 arrest and apoptosis in vitro. Excellent in vivo antitumor efficacy with 23 was achieved in an MV;411 mouse xenograft model. Pleasingly, compound 23 (hERG IC50 > 30 μM) mitigated the inhibition of the human ether-à-go-go-related gene (hERG) ion channel compared with 10 (hERG IC50 = 2.8 μM). This work provides a promising BD2-selective lead for the development of more effective and safe BET inhibitors as anticancer agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
- Institute of Innovative Drug Discovery and Development, China Pharmaceutical University, Nanjing 211198, China.
- Center for Chemical Biology and Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China.
- GMU-GIBH Joint School of Life Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
- China-New Zealand Joint Laboratory on Biomedicine and Health, Guangzhou, 510530, China.
- State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China.
ORCID-Profile: Kuojun Zhang, Yong Xu, Xiaoxing Wu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Jiang, W., Hou, Q., Xu, H., Yang, K., Wang, X., Zhang, K., Zeng, Y., Li, W., Wang, B., Luo, G., Zhao, X., Shen, H., Xu, Y., & Wu, X. (2024). Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 67(2), 1513-1532. https://doi.org/10.1021/acs.jmedchem.3c02104
Vancouver
Jiang W, Hou Q, Xu H, Yang K, Wang X, Zhang K, et al. Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia. Journal of Medicinal Chemistry. 2024;67(2):1513-1532. doi:10.1021/acs.jmedchem.3c02104
BibTeX
@article{Jiang2024,
author = {Jiang, Wenhua and Hou, Qiangqiang and Xu, Hongrui and Yang, Kexin and Wang, Xiaohui and Zhang, Kuojun and Zeng, Yi and Li, Wenqiang and Wang, Bingrui and Luo, Guangmei and Zhao, Xiaofan and Shen, Hui and Xu, Yong and Wu, Xiaoxing},
title = {Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {2},
pages = {1513--1532},
doi = {10.1021/acs.jmedchem.3c02104}
}
EUVIMED